Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Aspirin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
with unknown frequency (cannot be estimated from available data)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
this medicine
Do not store above 25°C. Store in the original package. Keep this medicine in a safe place out of the sight and reach of children, preferably in a locked cupboard. Use by the date on the end flap of the carton.
What is in this medicine
Each gastro-resistant tablet contains Aspirin 75 mg, which is the active ingredient. As well as the active ingredient, the tablets also contain potato starch, calcium hydrogen phosphate dihydrate (E341), microcrystalline cellulose (E460), talc (E553b), methacrylic acid-ethylacrylate – copolymer (containing sodium laurilsulfate, polysorbate 80), macrogol, simeticone. The pack contains 28 or 56 white, circular tablets, plain on both sides.
Who makes this medicine
Manufactured for The Boots Company PLC Nottingham NG2 3AA by the Marketing Authorisation holder Bristol Laboratories Ltd Unit 3 Canalside Northbridge Road Berkhamsted HP4 1EG. Boots Aspirin 75mg Gastro-resistant Tablets; PL 17907/0157, PL 17907/0158. Leaflet prepared September 2025. If you would like any further information about this medicine, please contact The Boots Company PLC Nottingham NG2 3AA.
PILXXXX
Boots Aspirin 75 mg Gastro-Resistant Tablets (P) comes as tablet containing 75mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Boots Aspirin 75 mg Gastro-Resistant Tablets (P) is aspirin.
Medicines with the same active substance, strength and form include: Boots Aspirin 75 mg Dispersible Tablets, Boots Aspirin 75 mg Gastro-Resistant Tablets (GSL), Aspirin 75 mg tablets. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Boots Aspirin 75 mg Gastro-Resistant Tablets (P), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ask anything about Boots Aspirin 75 mg Gastro-Resistant Tablets (P). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.